PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

RIZ1 and histone methylation status in pituitary adenomas.

Abstract RIZ1 displays strong tumor-suppressive activities, which has a potential histone methyltransferase activity. The objective of the study was to evaluate the level and the methylation status of RIZ1 and analyze its association with clinicopathological features and the histone in the pituitary adenomas. We found that RIZ1-positive cases were 11/50 and H-Scores 22.75 ± 11.83 in invasive pituitary adenomas and 26/53 and 66.3 ± 21.7 in non-invasive pituitary adenomas (χ(2) = 8.182, p = 0.004). RIZ1 and C-myc showed the opposite trend in these cases. The methylation levels of RIZ1 were more than 50% in 30.4% (7/23) CpG sites through MALDI-TOF Mass array. There was significant difference (p < 0.01) in 4 CpG sites between invasive pituitary adenoma group and non-invasive pituitary adenoma group; furthermore, the relieved methylation levels of H3K4/H3K9 and enhanced methylation levels of H3K27 in the patients' serum were found. Furthermore, there was statistic difference of H3K4 and H3K27 methylation between invasive pituitary adenoma and non-invasive pituitary adenoma group (p < 0.01). The average progression-free survival in high RIZ1 group was 52.63 ± 7.62 months and 26.06 ± 4.23 months in low RIZ1 group (p < 0.05). Promoter region methylation of RIZ1 may play an important role in the epigenetic silencing of RIZ1 expression in pituitary adenomas, which may translate into important diagnostic and therapeutic applications.
PMID
Related Publications

Decreased expression of retinoblastoma protein-interacting zinc-finger gene 1 in human esophageal squamous cell cancer by DNA methylation.

Aberrant Methylation of the 1p36 Tumor Suppressor Gene RIZ1 in Renal Cell Carcinoma.

Study on RIZ1 gene promoter methylation status in human esophageal squamous cell carcinoma.

DNA methylation of the RIZ1 tumor suppressor gene plays an important role in the tumorigenesis of cervical cancer.

Epigenetic inactivation of the tumor suppressor gene RIZ1 in hepatocellular carcinoma involves both DNA methylation and histone modifications.

Authors

Mayor MeshTerms

Epigenesis, Genetic

Keywords

Pituitary adenomas

RIZ1

histone

invasion

methylation

Journal Title tumour biology : the journal of the international society for oncodevelopmental biology and medicine
Publication Year Start




PMID- 28718376
OWN - NLM
STAT- MEDLINE
DA  - 20170718
DCOM- 20170726
LR  - 20170726
IS  - 1423-0380 (Electronic)
IS  - 1010-4283 (Linking)
VI  - 39
IP  - 7
DP  - 2017 Jul
TI  - RIZ1 and histone methylation status in pituitary adenomas.
PG  - 1010428317711794
LID - 10.1177/1010428317711794 [doi]
AB  - RIZ1 displays strong tumor-suppressive activities, which has a potential histone 
      methyltransferase activity. The objective of the study was to evaluate the level 
      and the methylation status of RIZ1 and analyze its association with
      clinicopathological features and the histone in the pituitary adenomas. We found 
      that RIZ1-positive cases were 11/50 and H-Scores 22.75 +/- 11.83 in invasive
      pituitary adenomas and 26/53 and 66.3 +/- 21.7 in non-invasive pituitary adenomas
      (chi2 = 8.182, p = 0.004). RIZ1 and C-myc showed the opposite trend in these
      cases. The methylation levels of RIZ1 were more than 50% in 30.4% (7/23) CpG
      sites through MALDI-TOF Mass array. There was significant difference (p &lt; 0.01)
      in 4 CpG sites between invasive pituitary adenoma group and non-invasive
      pituitary adenoma group; furthermore, the relieved methylation levels of
      H3K4/H3K9 and enhanced methylation levels of H3K27 in the patients' serum were
      found. Furthermore, there was statistic difference of H3K4 and H3K27 methylation 
      between invasive pituitary adenoma and non-invasive pituitary adenoma group (p &lt; 
      0.01). The average progression-free survival in high RIZ1 group was 52.63 +/-
      7.62 months and 26.06 +/- 4.23 months in low RIZ1 group (p &lt; 0.05). Promoter
      region methylation of RIZ1 may play an important role in the epigenetic silencing
      of RIZ1 expression in pituitary adenomas, which may translate into important
      diagnostic and therapeutic applications.
FAU - Xue, Yake
AU  - Xue Y
AD  - Department of Neurosurgery, The First Affiliated Hospital, Zhengzhou University, 
      Zhengzhou, China.
FAU - Chen, Ruokun
AU  - Chen R
AD  - Department of Neurosurgery, The First Affiliated Hospital, Zhengzhou University, 
      Zhengzhou, China.
FAU - Du, Wei
AU  - Du W
AD  - Department of Neurosurgery, The First Affiliated Hospital, Zhengzhou University, 
      Zhengzhou, China.
FAU - Yang, Fengdong
AU  - Yang F
AD  - Department of Neurosurgery, The First Affiliated Hospital, Zhengzhou University, 
      Zhengzhou, China.
FAU - Wei, Xinting
AU  - Wei X
AD  - Department of Neurosurgery, The First Affiliated Hospital, Zhengzhou University, 
      Zhengzhou, China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Tumour Biol
JT  - Tumour biology : the journal of the International Society for Oncodevelopmental
      Biology and Medicine
JID - 8409922
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (Histones)
RN  - 0 (Nuclear Proteins)
RN  - 0 (Transcription Factors)
RN  - EC 2.1.1.43 (Histone-Lysine N-Methyltransferase)
RN  - EC 2.1.1.43 (PRDM2 protein, human)
SB  - IM
MH  - Adult
MH  - Aged
MH  - DNA Methylation/*genetics
MH  - DNA-Binding Proteins/*genetics
MH  - Disease-Free Survival
MH  - *Epigenesis, Genetic
MH  - Female
MH  - Gene Expression Regulation, Neoplastic
MH  - Histone-Lysine N-Methyltransferase/*genetics
MH  - Histones/genetics
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nuclear Proteins/*genetics
MH  - Pituitary Neoplasms/*genetics/pathology
MH  - Promoter Regions, Genetic
MH  - Transcription Factors/*genetics
OTO - NOTNLM
OT  - Pituitary adenomas
OT  - RIZ1
OT  - histone
OT  - invasion
OT  - methylation
EDAT- 2017/07/19 06:00
MHDA- 2017/07/27 06:00
CRDT- 2017/07/19 06:00
AID - 10.1177/1010428317711794 [doi]
PST - ppublish
SO  - Tumour Biol. 2017 Jul;39(7):1010428317711794. doi: 10.1177/1010428317711794.